Journals on Congestive Heart Failure Treatment
"The treatment of congestive heart failure is complex and involves an interaction among lifestyle modifications, medications, and in some cases, electric or mechanical devices to assist the heart. Nonischemic heart failure including idiopathic dilative cardiomyopathy is not well known. It may vary considerably in different population sub-groups and geographic areas. In ambulatory and hospitalized patients with clinically manifest heart failure primary cardiomyopathy is diagnosed in 2-15%, while in recent large scale therapeutic trials the proportion of patients with nonischemic heart failure ranged from 18% to 53%. There is a relation between sex, age and etiology of chronic heart failure, nonischemic cardiomyopathy being more frequent in women and in younger individuals. In contrast to ischemic heart failure, where the severity usually correlates with the extent of coronary artery lesions, the pathophysiology of cardiomyopathy is less clear. Genetic factors, myocarditis from infectious agents, auto-immune mechanisms, cytokine activation, hormonal and metabolic influences can play a role. The functional consequences of myocardial damage in nonischemic heart failure are a global instead of localized abnormality of ventricular contractility. There is epidemiological evidence that in general the prognosis of nonischemic heart failure is better than in ischemic heart failure. The mortality of patients with ischemic heart failure was usually higher in the placebo groups of recent heart failure trials than in patients with nonischemic etiology. Furthermore, therapeutic responses to angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, amlodipine and amiodarone were also different in some studies. The outcome of nonischemic heart failure is better even in transplant candidates with the most advanced stages of heart failure, they survive longer and respond better to intensified drug regimens than patients with similar clinical severity of ischemic heart failure. Thus, an early and precise diagnosis of the etiology of heart failure should be encouraged not only in clinical trials but also in every day patient management. As more therapeutic options are developed, individualized drug selection for patients with various etiologies of heart failure may become possible. Impact Factor is a measure of the frequency with which the ""average article"" in a journal has been cited in a given period of time. The impact factor is used as standard dimension and the relative importance of a scientific journal within its field. The Impact Factor is calculated by several scientific methods including citation analysis. International Journal of Cardiovascular Research emerges as a best indexed journal with impact factor compared to other competitive journals focusing chronic ischemic heart disease and other cardiology studies by bringing up the recent research to global scientific community through its publications. The papers submitted are undergone through perfect plagiarism checks, later peer reviewed by the expert group and published after through revisions."